![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
5MB |
Preview |
PDF (Supplementary Data)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
739kB |
| Item Type: | Article |
|---|---|
| Title: | Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy |
| Creators Name: | Plewa, N., Poncette, L. and Blankenstein, T. |
| Abstract: | BACKGROUND: Adoptive transfer of patient’s T cells, engineered to express a T cell receptor (TCR) with defined novel antigen specificity, is a convenient form of cancer therapy. In most cases, major histocompatibility complex (MHC) I-restricted TCRs are expressed in CD8(+) T cells and the development of CD4(+) T cells engineered to express an MHC II-restricted TCR lacks behind. Critical is the choice of the target antigen, whether the epitope is efficiently processed and binds with high affinity to MHC molecules. A mutation in the transforming growth factor β receptor 2 (TGFβR2(-1)) gene creates a frameshift peptide caused by the deletion of one adenine (-1) within a microsatellite sequence. This somatic mutation is recurrent in microsatellite instable colorectal and gastric cancers and, therefore, is a truly tumor-specific antigen detected in many patients. METHODS: ABabDR4 mice, which express a diverse human TCR repertoire restricted to human MHC II molecule HLA-DRA/DRB1*0401 (HLA-DR4), were immunized with the TGFβR2(-1) peptide and TGFβR2(-1)-specific TCRs were isolated from responding CD4(+) T cells. The TGFβR2(-1)-specific TCRs were expressed in human CD4(+) T cells and their potency and safety profile were assessed by co-cultures and other functional assays. RESULTS: We demonstrated that TGFβR2(-1) neoantigen is immunogenic and elicited CD4(+) T cell responses in ABabDR4 mice. When expressed in human CD4(+) T cells, the HLA-DR4 restricted TGFβR2(-1)-specific TCRs induced IFNy expression at low TGFβR2(-1) peptide amounts. The TGFβR2(-1)-specific TCRs recognized HLA-DR4(+) lymphoblastoid cells, which endogenously processed and presented the neoantigen, and colorectal cancer cell lines SW48 and HCT116 naturally expressing the TGFβR2(-1) mutation. No MHC II alloreactivity or cross-reactivity to peptides with a similar TCR-recognition motif were observed, indicating the safety of the TCRs. CONCLUSIONS: The data suggest that HLA-DR4-restricted TCRs specific for the TGFβR2(-1) recurrent neoantigen can be valuable candidates for adoptive T cell therapy of a sizeable number of patients with cancer. |
| Keywords: | Neoplasm Antigens, CD8-Positive T-Lymphocytes, HLA-DR4 Antigen, Neoplasms, Peptides, T-Cell Antigen Receptors, Animals, Mice |
| Source: | Journal for ImmunoTherapy of Cancer |
| ISSN: | 2051-1426 |
| Publisher: | BMJ Publishing Group |
| Volume: | 11 |
| Number: | 2 |
| Page Range: | e006001 |
| Date: | February 2023 |
| Official Publication: | https://doi.org/10.1136/jitc-2022-006001 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
